<DOC>
	<DOCNO>NCT00050687</DOCNO>
	<brief_summary>This study test safety , tolerance , efficacy different dose oral gallium maltolate . Patients receive oral gallium maltolate twice daily 28-consecutive day follow 14 day treatment . This dose cycle repeat . Adverse effect assess level gallium serum measure . Any effect drug cancer improvement cancer-related symptom also measure .</brief_summary>
	<brief_title>Safety Pharmacokinetics Orally Administered Gallium Maltolate Various Refractory Malignancies</brief_title>
	<detailed_description>Gallium maltolate orally bioavailable form gallium . This safety , pharmacokinetic preliminary efficacy study . The primary objective study assess safety profile patient oral administration different dos gallium maltolate six 42-day cycle ( 28 day gallium maltolate , follow 14 day treatment ) . In addition , serum concentration gallium associate pharmacokinetic variable measure . From information , optimal dose select assessment anti-tumor efficacy . The study assess effect oral administration gallium maltolate pain result bony metastasis , biochemical measure bone turnover , disease progression overall survival patient various refractory malignancy . Patients may receive 6 cycle investigational agent .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Patients hormone refractory prostate cancer , refractory multiple myeloma , refractory bladder cancer , malignant lymphoma ; life expectancy ≥6 month , Zubrod Performance Status ≤2 , adequate bone marrow function , renal function , liver function pulmonary function ; age ≥ 18 year ; willing able give inform consent ; effective contraceptive use non childbearing potential . 10 % weight loss previous 3 month ; active serious infection control antibiotic ; initiation bisphosphonates treatment within 30 day ; participation research study within 30 day ; uncontrolled brain metastasis , prior intrathecal chemotherapy wholebrain radiotherapy , inability comply protocol undergo specified test ; active malignancy ; optic neuritis , routine use diuretic ( initial phase study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>